Biocytogen Pharmaceuticals and Myricx Bio Enter into Licence Agreement for ADC Development

Biocytogen Pharmaceuticals and Myricx Bio have entered into an antibody evaluation, option, and licence agreement to collaborate on the development of antibody drug conjugates (ADCs). 

This partnership leverages the strengths of both companies to create ADC drugs that have the potential to be first-in-class and best-in-class in the field of oncology.

This collaboration brings together the groundbreaking NMTi-based selective cytotoxic payloads with Biocytogen's expertise in antibody development for drug development purposes. This combination is expected to yield ADCs that can address significant clinical needs in the treatment of cancer.

NMT inhibitors represent a novel class of ADC payloads that hold promise as targeted therapies for cancer. These inhibitors work through a unique mechanism of action, which is distinct from traditional approaches to cancer treatment. ADC-NMTi has enormous potential for selectively killing cancer cells. This innovative approach offers a new way to target cancer with precision and effectiveness.

The collaboration between Biocytogen Pharmaceuticals and Myricx Bio aims to harness the strengths of both companies to develop groundbreaking ADCs that can provide significant advancements in cancer therapy. The use of NMT inhibitors as ADC payloads represents an exciting avenue for the development of selective and potent cancer treatments.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!